Quantdetect Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
2
- Latest Deal Type
-
Early Stage VC
- Investors
-
2
Quantdetect General Information
Description
Developer of sensitive diagnostic tools designed to track cancer-derived deoxyribonucleic acid. The company's technology determines deoxyribonucleic acid derived from blood tumors in cancer patients and provides genomic testing that tracks genomic information from cancer cells with personalized probes to evaluate post-therapeutic lesions, enabling medical professionals to navigate cancer treatment with unprecedented accuracy.
Contact Information
Website
www.quantdetect.comCorporate Office
- Tokyo Sankei Building 27th Floor
- 1-7-2 Otemachi, Chiyoda-ku
- Tokyo, 100-0004
- Japan
Corporate Office
- Tokyo Sankei Building 27th Floor
- 1-7-2 Otemachi, Chiyoda-ku
- Tokyo, 100-0004
- Japan
Quantdetect Timeline
Quantdetect Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Early Stage VC | 11-Sep-2023 | Completed | Generating Revenue | |||
2. Equity Crowdfunding | 15-Jun-2023 | Completed | Generating Revenue | |||
1. Seed Round | 17-Sep-2021 | $182K | $182K | Completed | Generating Revenue |
Quantdetect Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Class A preferred |
Quantdetect Patents
Quantdetect Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
JP-2024093463-A | Method for analyzing mutant dna associated with bladder cancer, and digital pcr primers and probes therefor | Pending | 27-Dec-2022 | ||
AU-2019315114-A1 | Probe/primer library for diagnosis of cancer | Pending | 31-Jul-2018 | ||
US-20220195527-A1 | Probe/primer library for diagnosis of cancer | Pending | 31-Jul-2018 | ||
EP-3831962-A4 | Probe/primer library for diagnosis of cancer | Pending | 31-Jul-2018 | ||
EP-3831962-A1 | Probe/primer library for diagnosis of cancer | Pending | 31-Jul-2018 | C12Q1/6886 |
Quantdetect Executive Team (1)
Name | Title | Board Seat |
---|---|---|
Satoshi Nishizuka Ph.D | Founder, President & Chief Executive Officer |
Quantdetect Signals
Quantdetect Investors (2)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Future Venture Capital | Venture Capital | Minority | ||
FVC Tohoku | Venture Capital | Minority |
Quantdetect FAQs
-
When was Quantdetect founded?
Quantdetect was founded in 2021.
-
Who is the founder of Quantdetect?
Satoshi Nishizuka Ph.D is the founder of Quantdetect.
-
Who is the CEO of Quantdetect?
Satoshi Nishizuka Ph.D is the CEO of Quantdetect.
-
Where is Quantdetect headquartered?
Quantdetect is headquartered in Tokyo, Japan.
-
What is the size of Quantdetect?
Quantdetect has 2 total employees.
-
What industry is Quantdetect in?
Quantdetect’s primary industry is Diagnostic Equipment.
-
Is Quantdetect a private or public company?
Quantdetect is a Private company.
-
What is Quantdetect’s current revenue?
The current revenue for Quantdetect is
. -
How much funding has Quantdetect raised over time?
Quantdetect has raised $290K.
-
Who are Quantdetect’s investors?
Future Venture Capital and FVC Tohoku have invested in Quantdetect.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »